Krishan Jethwa (@krishanjethwa) 's Twitter Profile
Krishan Jethwa

@krishanjethwa

GI Radiation Oncologist | Associate PD @MayoRadOnc @MayoClinic | Passions for #PatientCare, #MedEd, QoL, #PublicHealth, and #ClinicalTrials | Views are my own

ID: 787697800985268225

calendar_today16-10-2016 16:52:45

1,1K Tweet

3,3K Followers

1,1K Following

Krishan Jethwa (@krishanjethwa) 's Twitter Profile Photo
Krishan Jethwa
@krishanjethwa

a year ago

🚨🚨🚨PREOPANC-2 dropped! For AR or BR-PDAC, neoadjuvant FFX and neoadjuvant Gemcitabine based CRT (36 Gy/15 fx) had comparable outcomes. mOS was 21.9 m with FFX arm vs 21.3 m with CRT (HR 0.87; 95% CI 0.68-1.12, p=0.28), and similar resection rates 77% vs. 75%. #ESMO23

🚨🚨🚨PREOPANC-2 dropped! For AR or BR-PDAC, neoadjuvant FFX and neoadjuvant Gemcitabine based CRT (36 Gy/15 fx) had comparable outcomes. mOS was 21.9 m with FFX arm vs 21.3 m with CRT (HR 0.87; 95% CI 0.68-1.12, p=0.28), and similar resection rates 77% vs. 75%. #ESMO23